top of page

Research That Lives Where You Live

Breakthrough cancer care … delivered with compassion, right here close to home.

Through clinical research, we bring new possibilities to patients and families when they

need them most.

No Clinical Trials Found

Clinical Trials Found

EmpowHER Ph3

Zanidatamab (HER2 bispecific antibody) in combination with MD-choice therapy, in patients who have progressed on or are intolerant to trastuzumab deruxtecan. At least 2 lines of HER2-directed therapy.

​

Bria Cell

IP: T-cell vaccine. Prior treatment with at least 3 regimens, including at least 2 anti-HER2 and one chemo-containing regimen.

​

Roche neoTOV (Ph2)

PIK3CA-mutant. Untreated stage II–III. IP: Inavolisib, Ribociclib, Letrozole.

​

Roche CO46274

Chromosome 8p loss and PIK3CA wild-type. IP: Inavolisib + Ribociclib + Fulvestrant vs Placebo + Ribociclib + Fulvestrant. Progressed during adjuvant ET or within 12 months after completing AI or tamoxifen.

​

KATSIS-1 (Pfizer C4551002)

Progression on CDK4/6 + ET — adjuvant and metastatic.

​

Merck Herthena-04

HER3 ADC. After progression on CDK4/6 + ET. No other mutations present.

​

KATSIS-1 (Pfizer C4551002)

Adjuvant CDK4/6 + ET allowed — during or within 12 months of last dose. OK for Orserdu; no PIK3CA.

​

OptINAVO (WO46063)

PIK3CA-mutant. Disease progression during or after treatment with CDK4/6i + ET. 1L of systemic therapy allowed.

​

PUMA

Alisertib plus endocrine therapy. Progression on or after 2 lines of ET; must have received CDK4/6 in combination. Study arms: 50 mg, 40 mg, 30 mg plus ET.

​

BRIA Cell (HER2-neg / HER2-low)

HER2-negative / HER2-low, refractory to hormonal therapy and previously treated with at least 2 chemo regimens.

​

ASCENT-05 (GSUS5956184)

TEMPORARY PAUSE 07/10/26. Adjuvant TNBC. Post-neoadjuvant treatment, residual disease at surgery. Arm A: Sacituzumab Govitecan + Pembrolizumab. Arm B: MD's chemo choice.

​

TROPION 5

DE NOVO COHORT CLOSED 11SEP2026. No prior treatment. PD-L1 >10. Arm A: Dato-DXd + Immunotherapy. Arm B: SOC. Recurrent disease, DFI of 6–12 months or greater.

​

Gilead 7321

Phase 1/2 alternative dose and schedule of Sacituzumab Govitecan. Phase 1 closed; Phase 2 pending.

​

Bria Cell

Exhausted all curative intent; at least 2 prior chemo.

​

Opera-2

EARLY SSU. Advanced ER-positive, HER2-negative breast cancer. Palazestrant given with Ribociclib.

​

ARTEMIDE 02 SCC

Squamous NSCLC; PD-L1 TC ≥1%. Double-blind study of Rilvegostomig (PD-L1/TIGIT) or Pembrolizumab in combination with platinum-based chemo.

​

ARTEMIDE 03

Non-squamous NSCLC; PD-L1 TC ≥1%. Double-blind study of Rilvegostomig or Pembrolizumab in combination with platinum-based chemo (PD-L1 low expression).

​

Pfizer SYMBIOTIC Lung 01 (C6461001)

PD-L1 all comers, squamous or non-squamous. PF-08634404 — tetravalent bispecific PD-1 and VEGF — vs Pembrolizumab + chemo.

​

EIKON TeLuRide 008

Phase 3, double-blind, placebo-controlled: EIK1001 (TLR 7/8 agonist) in combination with Pembrolizumab and chemo.

​

HARMONI 7

PAUSED FOR ENROLLMENT. Squamous or non-squamous NSCLC; PD-L1 high >50%. Phase 3 study of Ivonescimab vs Pembrolizumab.

​

Tropion 10

Non-squamous NSCLC; PD-L1 TC ≥50%; high PD-L1 and without AGA. Phase 3: Dato-DXd in combination with Rilvegostomig, or Rilvegostomig mono, vs Pembrolizumab mono.

​

Destiny Lung 06

EGFR-/Her2+. HER2 overexpression; PD-L1 <50%. Trastuzumab Deruxtecan in combination with Pembrolizumab vs Pembrolizumab with platinum-based chemotherapy.

​

ASTELLAS Setidegrasib

EGFR+/KRAS G12D. KRAS G12D. Setidegrasib vs Docetaxel in patients who progressed after platinum-based chemo and CPI.

​

Rainfol-05 / RINA-S

KRAS G12C. Antibody-drug conjugate targeting folate receptor alpha, delivering a Topo1 inhibitor payload. Multiple cohorts, including EGFR-mutated and KRAS G12C.

​

EVOKE SCLC 04

Phase 3: Sacituzumab Govitecan vs SOC in previously treated extensive-stage SCLC.

​

C5751005

EARLY SSU. Advanced non-squamous NSCLC. Sigvotatug Vedotin + Pembrolizumab, with or without Carboplatin.

​

KRASCENDO-3 (BO45885)

APPROACHING SIV. Resected stage II/III, KRAS G12C+. Divarasib vs Investigator’s Choice.

​

Divarasib — Early Access Program

EARLY SSU. KRAS G12C NSCLC.

​

Harmoni-10

EARLY SSU. Unresectable stage III NSCLC. Ivonescimab vs Durvalumab consolidation therapy.

​

C6461004

Extensive-stage SCLC, treatment-naïve.

​

C6461014

Transformed SCLC.

​

SystImmune

Extensive-stage SCLC. Bispecific ADC + T-cell engager.

​

Henlius PHAROS001

ALL DRUGS PROVIDED BY SPONSOR. Phase 3, HER2+. IP: HLX22 (anti-HER2) in combination with Trastuzumab and chemo (XELOX) vs Trastuzumab and XELOX, with or without Pembrolizumab.

​

AZ GEMINI

ENROLLMENT PAUSED. Phase 3, HER2-negative and Claudin 18.2. IP: AZD0901 (ADC with Claudin 18.2) plus Rilvegostomig plus 5-FU or Capecitabine.

​

BeOne

Phase 2. IP: Tislelizumab plus chemo (Xeloda, 5-FU, Oxaliplatin, Leucovorin). Advanced unresectable gastric adenocarcinoma, esophageal SCC, advanced gastroesophageal — in US racial and ethnic minority populations.

​

Artemide — Gastric01

HER2+ (HER2 3+ or 2+/ISH-positive), CPS ≥1. Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan vs Trastuzumab, Chemotherapy & Pembrolizumab.

​

SymbioticGI-16

HER2-negative, PD-L1 positive. PF-08634404 (tetravalent bispecific antibody) + chemotherapy.

​

Destiny BTC-01

Phase 3, biliary tract cancer. IP: T-DXd and Rilvegostomig vs SOC. Histologically confirmed HER2-expressing (IHC 3+ or IHC 2+) BTC; unresectable, previously untreated, locally advanced or metastatic. Prior perioperative/adjuvant treatment permissible provided >6 months (180 days) between end of adjuvant treatment and diagnosis of advanced disease.

​

GENFIT

SCREENING PER SPONSOR APPROVAL. Phase 1b/2a, advanced KRAS-mutant cholangiocarcinoma. IP: GNS561 (PPT1 inhibitor) in combination with Trametinib (MEK1/2 inhibitor).

​

INCB161734-303 (DAWN-303)

Randomized, double-blind Phase 3: chemo with or without INCB161734 (KRAS G12D inhibitor) in previously untreated pancreatic adenocarcinoma. KRAS G12D mutated — documented in tumor tissue or blood. Stable, treated brain mets allowed.

​

IDeate-Esophageal01

EARLY SSU. I-DXd in pretreated ESCC; progression post platinum-based chemotherapy and an ICI treatment.

​

BGB-B2033

EARLY SSU. R/R HCC; ≥1 prior lines of systemic therapy (containing PD-1/PD-L1); Child-Pugh Class A. Arm A: BGB-B2033 450 mg, IV, Q3W. Arm B: Investigator choice of Lenvatinib (8/12 mg PO, QD) or Sorafenib (400 mg PO, BID).

​

MOUNTAINEER 03

8 SLOTS LEFT 10/05/2026. Phase 3, HER2+, RAS wild-type. IP: Tucatinib & Herceptin + mFOLFOX6 vs SOC. Sponsor will test HER2+ (good for a year until enrollment).

​

OrigAmi2

Phase 3, treatment-naïve patients with KRAS/NRAS and BRAF wild-type. IP: Amivantamab + chemo vs Cetuximab + chemo. Left-sided colon cancer only.

​

Merck KANDLELIT-012

Phase 3, KRAS G12C-mutant. IP: MK-1084 (oral selective KRAS G12C covalent inhibitor) with Cetuximab and mFOLFOX6, with or without Bevacizumab.

​

Harmoni-Gi3

Phase 3, double-blind. IP: Ivonescimab (bispecific antibody PD-1 and VEGF) in combination with FOLFOX vs Bevacizumab with FOLFOX.

​

INCYTE INCA-303

1L mCRC (no MSI-H, dMMR or BRAF V600E mutation). INCA33890 + FOLFOX + Bevacizumab vs Placebo + FOLFOX + Bevacizumab.

​

OrigAmi3

LAST PATIENT IN (SCREENED): 30-NOV-2026 · LAST PATIENT DOSED: 31-DEC-2026. Phase 3, patients with KRAS/NRAS and BRAF wild-type; recurrent, unresectable or metastatic CRC. IP: Amivantamab + FOLFIRI vs Cetuximab/Bevacizumab + FOLFIRI.

​

GCT1158-08

EARLY SSU · NOT ENROLLING YET 08/06/2026. RAS/BRAF wild-type mCRC (Part 2). Petosemtamab + mFOLFOX6 or FOLFIRI vs Cetuximab with mFOLFOX6 or FOLFIRI. Left-sided colon cancer only.

​

MEVPRO2

CLOSING SOON – NOV 2026. Phase 3, randomized, double-blind, placebo-controlled study of Mevrometostat with Enzalutamide in metastatic castration-resistant prostate cancer. Treatment-naïve.

​

Himalayas-1

APPROACHING SIV · NOT ENROLLING YET 08/06/2026. mCRPC previously treated with Abiraterone Acetate. Progression on treatment with abiraterone acetate in the mCSPC setting or first-line mCRPC.

​

T-Bren

EARLY SSU. HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy. T-Bren vs platinum-based chemotherapy.

​

TROPION-Urothelial03

EARLY SSU. Progressed during or after Enfortumab Vedotin (EV) plus Pembrolizumab combination treatment. Arm A: Dato-DXd + Carboplatin or Cisplatin (physician choice). Arm B: Gemcitabine + Carboplatin or Cisplatin (physician choice).

​

IDeate-Pantumor 02 (Daiichi)

Phase 1b/2 study of Ifinatamab Deruxtecan in R/M solid tumors. Stage 2 enrollment for UC: 7 slots available for patients with prior EV + Pembro concurrent therapy (07/01/2026); requires sponsor approval. Sites: GS, Century, Pas, Anaheim, FV.

​

GLORA

Phase 3 registrational study of Lisaftoclax. Previously treated CLL/SLL on 1st, 2nd or 3rd line therapy; at least 12 months of previous Acalabrutinib monotherapy, stable disease. Inv. arm: Lisaftoclax in combination with Acalabrutinib.

​

Takeda RENEW (KER-050-D301)

Phase 3: Elritercept (activin inhibitor), double-blind. Transfusion-dependent anemia — MDS.

​

DREAMM-10

Belantamab mafodotin with Lenalidomide and Dexamethasone (BRd) vs standard Daratumumab-based therapy (DRd).

​

NX-5948-306

SIV READY · NOT ENROLLING YET 08/06/2026. RR CLL/SLL. NX-5948 (bexobrutideg) vs pirtobrutinib. Received at least one prior line of therapy for CLL/SLL that included a cBTKi, with documented disease progression during treatment with, or after discontinuation of, the cBTKi.

​

WaveLINE-010

EARLY SSU · NOT ENROLLING YET 08/06/2026. Zilovertamab Vedotin (MK-2140) in combination with R-CHP vs R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).

​

GLOSEEK-4 (CA073-1003)

NOT ENROLLING YET 08/06/2026. RR follicular lymphoma. Golcadomide in combination with Rituximab (Golca + R) vs Investigator’s Choice, in participants who have received at least 1 prior line of systemic therapy.

​

Dommino-2

EARLY SSU. Inobrodib in combination with Pomalidomide and Dexamethasone vs standard available therapy. RRMM — 1–4 prior lines.

​

ELRISE MF

SIV READY. Myelofibrosis & anemia. A study to compare Elritercept to Placebo in adults with myelofibrosis and anemia who are taking Ruxolitinib.

​

RAINFOL-10 (GENMAB GCT1184-10)

NOT ENROLLING YET 08/06/2026 · PENDING GOG ADMISSION. Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment in Participants With Ovarian Cancer Following First-Line (1L) Platinum-Based Chemotherapy.

​

DENALI (Zentalis ZN-c3-005)

NOT ENROLLING YET 08/06/2026 · PENDING GOG ADMISSION. High-grade serous ovarian, fallopian tube, or primary peritoneal cancer. ZN-c3 (azenosertib) is an investigational, highly selective oral WEE1 kinase inhibitor, developed for targeted cancer therapy — forcing cancer cells (especially those with p53 mutations) into premature cell division, leading to DNA damage and cell death.

​

ASPENOVA (Zentalis ZN-c3-020)

NOT ENROLLING YET 08/06/2026 · PENDING GOG ADMISSION. A Study of Azenosertib (ZN-c3) Versus Investigator’s Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression.

​

TROPION-SWISH (D926UL00001)

Daily prophylaxis with Dexamethasone mouthwash at start of 1st infusion and throughout Dato-DXd administration. Cohorts: post-ET & post-chemo HER2+/HER2- mBC; inoperable locally advanced or metastatic IO-ineligible TNBC; advanced or metastatic EGFRm NSCLC.

​

TROPION-SWISH (D926UL00001)

Daily prophylaxis with Dexamethasone mouthwash at start of 1st infusion and throughout Dato-DXd administration. Cohorts: post-ET & post-chemo HER2+/HER2- mBC; inoperable locally advanced or metastatic IO-ineligible TNBC; advanced or metastatic EGFRm NSCLC.

​

TROPION-SWISH (D926UL00001)

Daily prophylaxis with Dexamethasone mouthwash at start of 1st infusion and throughout Dato-DXd administration. Cohorts: post-ET & post-chemo HER2+/HER2- mBC; inoperable locally advanced or metastatic IO-ineligible TNBC; advanced or metastatic EGFRm NSCLC.

​

Pan-Tumor MRD Study

NOT ENROLLING AS OF 08/06/2026. Molecular Residual Disease in solid tumors: a prospective study to collect clinical data and biospecimens to support the discovery and development of cancer biomarkers.

​

Supportive Care

Breast Cancer

Post-ET & Post-Chemo — Her2+/Her2- mBC

Principal Investigator (PI)

ClinicalTrials.gov

Protocol #

​

TROPION-SWISH (D926UL00001)

Daily prophylaxis with Dexamethasone mouthwash at start of 1st infusion and throughout Dato-DXd administration. Cohorts: post-ET & post-chemo HER2+/HER2- mBC; inoperable locally advanced or metastatic IO-ineligible TNBC; advanced or metastatic EGFRm NSCLC.

Sponsor

​

​

Supportive Care

Breast Cancer

Inoperable Locally Advanced or Metastatic IO-ineligible TNBC

Principal Investigator (PI)

ClinicalTrials.gov

Protocol #

​

TROPION-SWISH (D926UL00001)

Daily prophylaxis with Dexamethasone mouthwash at start of 1st infusion and throughout Dato-DXd administration. Cohorts: post-ET & post-chemo HER2+/HER2- mBC; inoperable locally advanced or metastatic IO-ineligible TNBC; advanced or metastatic EGFRm NSCLC.

Sponsor

​

​

Supportive Care

Lung Cancer

Advanced or Metastatic EGFRm NSCLC

Principal Investigator (PI)

ClinicalTrials.gov

Protocol #

​

TROPION-SWISH (D926UL00001)

Daily prophylaxis with Dexamethasone mouthwash at start of 1st infusion and throughout Dato-DXd administration. Cohorts: post-ET & post-chemo HER2+/HER2- mBC; inoperable locally advanced or metastatic IO-ineligible TNBC; advanced or metastatic EGFRm NSCLC.

Sponsor

​

​

Supportive Care

Blood Collection

​

Principal Investigator (PI)

ClinicalTrials.gov

Protocol #

​

Pan-Tumor MRD Study

NOT ENROLLING AS OF 08/06/2026. Molecular Residual Disease in solid tumors: a prospective study to collect clinical data and biospecimens to support the discovery and development of cancer biomarkers.

Sponsor

​

​

Interested in learning more about clinical trials or research opportunities?

Our team is here to help answer questions and support next steps.

Oncura Heath provides education and care coordination related to clinical trials.

We do not provide medical advice or determine eligibility. All treatment decisions are made between patients and their physicians.

bottom of page